New treatment tested for painful genital eczema

NCT ID NCT07444801

Summary

This study is observing how well an existing eczema medication called tralokinumab works for people whose moderate-to-severe eczema affects their genital area. Over 52 weeks, researchers will track 30 adult patients who are already starting this treatment as part of their regular care. They will measure changes in symptoms, skin appearance, and quality of life using specific questionnaires and imaging tools.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (MODERATE-TO-SEVERE) INVOLVING THE GENITAL REGION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CCIM, Institut für Entzündungsmedizin UKSH Lübeck

    RECRUITING

    Lübeck, Schleswig-Holstein, 23538, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Department of Dermatology of the University Hospital Augsburg

    RECRUITING

    Augsburg, München, 86156, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.